NDC product
NEMLUVIO
NDC 0299-6220 · Galderma Laboratories, L.P.
Key facts
| Product NDC | 0299-6220 |
|---|---|
| Proprietary name | NEMLUVIO |
| Nonproprietary name | nemolizumab-ilto |
| Substances | NEMOLIZUMAB |
| Dosage form | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION |
| Route | SUBCUTANEOUS |
| Labeler | Galderma Laboratories, L.P. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | BLA |
| Application number | BLA761390 |
| Pharmacologic classes | Interleukin-31 Receptor alpha Antagonist [EPC], Interleukin-31 Receptor alpha Antagonists [MoA] |
| Marketing start | Aug 13, 2024 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: